Neurotech Demonstrates Potential Benefits for Management of Multiple Sclerosis Disease
Neurotech International Limited (ASX:NTI) has announced the continuation of its pre-clinical program in neuro-inflammatory disease models in-line with its research and development pathway.
Initial in vitro studies were carried out in collaboration with the internationally recognised Neurodevelopment in Health and Disease Laboratory at RMIT University to assess the effects of the lead NTI/Dolce strains on key neuro-markets that are used in assessing the onset and progression of Multiple Sclerosis (MS).
Summarised in the table below, the results reconfirm the powerful neuro-modulatory, neuro-regulatory and neuro anti-inflammatory properties of the novel NTI/Dolce Strains compared to CBD alone in supressing the neuro-inflammatory markers, GM-CSF and TNF-alpha, in a neural cell-line culture.
These preclinical studies will pave the way for further expansion and analysis of other neuro-markers involved in MS.
There is a strong medical need for treatment alternatives which include the potential of utilising the NTI/Dolce Strains given they have < 0.3% THC and a full spectrum cannabinoid profile that has already demonstrated the activation of alternative anti-inflammatory neuro modulatory pathways that differ considerably to CBD alone products.
Key neuro-markers involved in the onset and progression of MS include:
- Granulocyte Granulocyte-macrophage colony-stimulating factor (GM-CSF)
- Tumour Necrosis Factor (TNF-alpha)
- Interferon (IFN)
- Interleukins (IL-2)
NTI is committed to the development of a solid scientific portfolio for the expansion of application and use of the NTI/Dolce Strains beyond autism. Further preclinical studies will determine mode of action and safety to design and undertake a Phase I/II clinical study in MS.
“There are a number of very powerful neuro-markers that are currently being used to assess disease onset and progression,” said Brian Leedman, Chairman of Neurotech. “To be able to suppress or regulate these markers may be very beneficial in the overall disease management”.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.